Maxcyte (MXCT) EBIT Margin (2020 - 2025)
Maxcyte (MXCT) has disclosed EBIT Margin for 6 consecutive years, with 307.39% as the latest value for Q3 2025.
- On a quarterly basis, EBIT Margin fell 5698.0% to 307.39% in Q3 2025 year-over-year; TTM through Sep 2025 was 279.76%, a 25706.0% decrease, with the full-year FY2024 number at 230.46%, down 18961.0% from a year prior.
- EBIT Margin was 307.39% for Q3 2025 at Maxcyte, down from 167.24% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 677.99% in Q4 2023 to a low of 4358.45% in Q4 2024.
- A 5-year average of 341.58% and a median of 108.23% in 2024 define the central range for EBIT Margin.
- Peak YoY movement for EBIT Margin: skyrocketed 76502bps in 2023, then crashed -503643bps in 2024.
- Maxcyte's EBIT Margin stood at 48.81% in 2021, then plummeted by -78bps to 87.04% in 2022, then soared by 879bps to 677.99% in 2023, then tumbled by -743bps to 4358.45% in 2024, then surged by 93bps to 307.39% in 2025.
- Per Business Quant, the three most recent readings for MXCT's EBIT Margin are 307.39% (Q3 2025), 167.24% (Q2 2025), and 214.09% (Q1 2025).